|
|
|
|
Managing Directors |
Immanuel Thangaraj has 17 years of experience in operations and venture capital. Mr. Thangaraj began his venture career at ARCH Venture Partners ("AVP"), a leading venture capital firm with over $2 billion under management, which makes early stage technology and healthcare investments. In his initial tenure at AVP, he managed one of its portfolio companies, HealthQual, a medical information company, until its sale to Nellcor, a large hospital supplies company. In 1995, Mr. Thangaraj left AVP to run a telecommunications company until its sale to a public company.
Mr. Thangaraj joined Essex Woodlands in 1996. He currently serves on the
Board of Directors of
CBR Systems, Inc.,
Acura Pharmaceuticals, Inc. (formerly
Halsey Pharmaceuticals) (NASDAQ: ACUR), Clear Vascular, Inc.,
Proteus Biomedical, Inc.,
Medlogics Device Corporation, and
Sound
ID. He is also responsible for Essex Woodland’s investment in
Novacept
(sold to Cytyc) and two Chinese companies, Microport
Medical (Shanghai) Co. Ltd and China Cord Blood Services Corporation.
Mr. Thangaraj holds a B.A. and a M.B.A. from the University of Chicago. |
|
|
 |
|
|
|
